Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical device
artificial pancreas |
| gptkbp:clinicalTrialPhase |
2022 multi-center study
|
| gptkbp:deliveredBy |
subcutaneous infusion
|
| gptkbp:FDAApproved |
2023
|
| gptkbp:features |
algorithm-based glucose control
automated insulin dosing minimal user input |
| https://www.w3.org/2000/01/rdf-schema#label |
iLet Bionic Pancreas
|
| gptkbp:intendedUse |
diabetes management
|
| gptkbp:manufacturer |
gptkb:Beta_Bionics
|
| gptkbp:regulates |
gptkb:glucagon
gptkb:insulin blood glucose |
| gptkbp:requires |
continuous glucose monitor
insulin cartridges |
| gptkbp:targetAudience |
Type 1 diabetes patients
|
| gptkbp:website |
https://www.betabionics.com/ilet-bionic-pancreas
|
| gptkbp:bfsParent |
gptkb:Beta_Bionics
|
| gptkbp:bfsLayer |
8
|